FindTrial
Sign In

To determine the amount of propofol (a sedative drug), needed for sedating patients undergoing Endoscopic retrograde cholangiopancreatography by using a target control infusion pump.

To determine the target effector concentration (Ce) of Propofol needed to achieve sedation in patients undergoing Endoscopic Retrograde Cholangiopancreatography - A Target Control Infusion operated approach. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/057623
Enrollment
100
Registered
2023-09-14
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K87- Disorders of gallbladder, biliarytract and pancreas in diseases classified elsewhere

Interventions

Intervention1: TARGET CONTROL INFUSION: WE WILL USE TARGET CONTROL INFUSION PUMP TO DETERMINE THE PLASMA CONCENTRATION OF INTRAVENOUS PROPOFOL AT WHICH ERCP CAN BE PERFORMED COMFORTABLY WITH MINIMAL S

Sponsors

INSTITUTE OF LIVER AND BILIARY SCIENCES
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA-1 AND 2 PATIENTS

Exclusion criteria

Exclusion criteria: DECOMPENSATED LIVER CIRRHOSIS, POST LIVER TRANSPLANT, PATIENTS ALLERGIC TO PROPOFOL AND ITS CONTENTS

Design outcomes

Primary

MeasureTime frame
To determine Target effector concentration (Ce) of Propofol needed to achieve sedation (BIS 50-70) in patients undergoing ERCP.Timepoint: intraprocedural—

Secondary

MeasureTime frame
TO DETERMINE HEMODYNAMIC PROFILE, RECOVERY PROFILE, TOTAL CONSUMPTION OF PROPOFOL AND ADVERSE EFFECTS OF PROPOFOL INFUSION VIA TCI PUMP IN ERCPTimepoint: PERIPROCEDURAL—

Countries

India

Contacts

Public ContactSURBHI

INSTITUTE OF LIVER AND BILIARY SCIENCES

uddh1989@gmail.com8861987684

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026